SCHEMBL23927191

SCHEMBL23927191

O=C1CN=C(c2c(F)cccc2F)c2c(ccc(C(F)(F)F)c2Cl)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
GABRA1 P14867 7/20 0.44
GABRA5 P31644 7/20 0.44
GABRA3 P34903 7/20 0.44
GABRA2 P47869 7/20 0.44
GABRB2 P47870 6/20 0.44
GABRG2 P18507 5/20 0.44
GABRB3 P28472 5/20 0.44
GABRP O00591 3/20 0.44
GABRD O14764 3/20 0.44
GABRB1 P18505 3/20 0.44
GABRA4 P48169 3/20 0.44
GABRE P78334 3/20 0.44
GABRA6 Q16445 3/20 0.44
GABRG1 Q8N1C3 3/20 0.44
GABRG3 Q99928 3/20 0.44
GABRQ Q9UN88 3/20 0.44
CNR1 P21554 1/20 0.39
NTSR1 P30989 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23927177 0.88 LMNA (0.60) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL30202195 0.88 LMNA (0.60) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL23927211 0.86 CHRM1 (0.47) LMNANOTUM
SCHEMBL23927200 0.85 LMNA (0.43) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL23927197 0.85 LMNA (0.51) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL23927214 0.83 LMNA (0.49) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL23881540 0.83 GABRA1 (0.49) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL30133111 0.83 GABRA1 (0.49) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL23881526 0.83 LMNA (0.49) LMNAGABRA1GABRA5GABRA3GABRA2
SCHEMBL23927174 0.80 GABRA1 (0.55) LMNAGABRA1GABRA5GABRA3GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008781-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (US) 2026-01-08 US disclosed
EP-4408848-B1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS HOFFMANN LA ROCHE (CH) 2025-11-05 EP disclosed
US-12365687-B2 Benzodiazepine derivatives as GABA A gamma 1 PAM HOFFMANN-LA ROCHE INC. (US) 2025-07-22 US disclosed
EP-4408848-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2024-08-07 EP disclosed
EP-4405043-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2024-07-31 EP disclosed
CN-118019742-A Novel benzodiazepine derivatives as GABA Aγ1 PAM 豪夫迈·罗氏有限公司 2024-05-10 CN disclosed
EP-4139310-B1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (CH) 2024-03-27 EP disclosed
US-20230141603-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-11 US disclosed
US-20230136326-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA 1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-04 US disclosed
US-20230136326-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA 1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-04 US disclosed
WO-2023052312-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. HOFFMANN-LA ROCHE AG (CH) 2023-04-06 WO disclosed
WO-2023046817-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. HOFFMANN-LA ROCHE AG (CH) 2023-03-30 WO disclosed
EP-4139310-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
WO-2021213952-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901155-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365687-B2 Benzodiazepine derivatives as GABA A gamma 1 PAM GABRA1, GABRB1, GABRG1 LMNA 2569/4885GABRA1 1/4885GABRA5 4/4885
US-20230136326-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA 1 PAM GABRA1, GABRB1, GABRA5 LMNA 2641/4885GABRA1 1/4885GABRA5 3/4885
US-20260008781-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRA6, GABRB1 LMNA 2020/4885GABRA1 1/4885GABRA5 7/4885
US-20230141603-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRB1, GABRB3 LMNA 2279/4885GABRA1 1/4885GABRA5 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.